Since CD44+/CD133+ cells account for an important subpopulation of hepatic CSCs (26), immunofluorescent analysis further confirmed that LECT2 therapy significantly decreased the CD44+/CD133+ hepatic CSCs in Novikoff hepatoma (∗∗p < 0.01; Fig. 6E). The gene discussed is LECT2; the disease is hepatocellular carcinoma.